Literature DB >> 16244805

Effectiveness of palliative procedures for intra-abdominal sarcomas.

Jen Jen Yeh1, Samuel Singer, Murray F Brennan, David P Jaques.   

Abstract

BACKGROUND: Nearly half of patients with intra-abdominal (retroperitoneal, visceral, or pelvic) sarcoma undergo more than one operation. When the objective shifts from cure to palliation, the clinical quandary of doing no harm and maximizing benefit is magnified. Knowledge of the effectiveness of a procedure at achieving its palliative intent, as well as its attendant morbidity and mortality, is therefore paramount during this deliberation.
METHODS: A retrospective review was performed of all patients with a diagnosis of intra-abdominal sarcoma who underwent a palliative procedure between 1982 and 2003. A procedure was defined as palliative if it was explicitly performed to relieve symptoms.
RESULTS: Ten percent (112 of 1084) of patients with a diagnosis of intra-abdominal sarcoma underwent a total of 156 palliative procedures. The most frequent system for which a palliative procedure was performed was gastrointestinal (68 of 156; 44%). Overall, 71% of patients had improvement of symptoms 30 days after the operation, whereas only 54% of patients remained symptom free after 100 days. Although 54% of gastrointestinal tract obstructive symptoms were successfully relieved at 30 days, only 23% of patients remained symptom free at 100 days. The overall operative morbidity was 29%, and postoperative mortality was 12%. Patients undergoing procedures intended to palliate gastrointestinal obstruction encountered the greatest morbidity (19 of 40; 48%).
CONCLUSIONS: Successful palliation of many symptoms associated with advanced intra-abdominal sarcoma may be achieved. However, even in highly selected patients, the progressive and pervasive nature of the disease limits the opportunity to attain sustained relief for gastrointestinal obstructive symptoms.

Entities:  

Mesh:

Year:  2005        PMID: 16244805     DOI: 10.1245/ASO.2005.03.016

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Surgery for retroperitoneal soft tissue sarcomas: aggressive re-resection of recurrent disease is possible.

Authors:  R Lochan; J J French; D M Manas
Journal:  Ann R Coll Surg Engl       Date:  2010-09-07       Impact factor: 1.891

Review 2.  Surgical management of retroperitoneal and pelvic sarcomas.

Authors:  Marcus C B Tan; Sam S Yoon
Journal:  J Surg Oncol       Date:  2014-12-05       Impact factor: 3.454

Review 3.  [Surgical therapy of abdominal and trunk soft tissue sarcomas].

Authors:  S Schimmack; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

4.  Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

Authors:  M Toulmonde; S Bonvalot; I Ray-Coquard; E Stoeckle; O Riou; N Isambert; E Bompas; N Penel; C Delcambre-Lair; E Saada; A Lecesne; C Le Péchoux; J Y Blay; S Piperno-Neumann; C Chevreau; J O Bay; V Brouste; P Terrier; D Ranchère-Vince; A Neuville; A Italiano
Journal:  Ann Oncol       Date:  2014-02-03       Impact factor: 32.976

5.  Predictors of intensive care unit admission and related outcome for patients after pancreaticoduodenectomy.

Authors:  David J Bentrem; Jen J Yeh; Murray F Brennan; Ravi Kiran; Stephen M Pastores; Neil A Halpern; David P Jaques; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

Review 6.  Retroperitoneal Sarcoma Care in 2021.

Authors:  Erika Schmitz; Carolyn Nessim
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

7.  Radical palliative surgery: new limits to pursue.

Authors:  Mindy Young-Spint; Yigit S Guner; Frederick J Meyers; Phillip Schneider; Vijay P Khatri
Journal:  Pediatr Surg Int       Date:  2009-10       Impact factor: 1.827

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.